PC-01 — What Are Peptides and Why Is Everyone Talking About Them?

What Peptides Actually Are

Peptides are short chains of amino acids — the building blocks of proteins. When a chain of amino acids is long enough, it becomes a protein. When it's shorter — typically between 2 and 50 amino acids — it's classified as a peptide.

Your body produces peptides naturally. They function as signaling molecules: telling cells what to do, regulating hormones, coordinating immune responses, facilitating repair processes. Insulin is a peptide. Growth hormone-releasing peptides are peptides. The naturally occurring BPC-157 your body makes in the gut is a peptide.

Because peptides are naturally occurring and because many of them have well-characterized mechanisms of action, researchers have spent decades studying which exogenous peptides — peptides administered from outside the body — might support specific physiological processes. That research has produced both FDA-approved peptide drugs and a large灰色 market of compounded peptides used off-label.

The key distinction that matters for everything else:

• FDA-approved peptide drugs have been through clinical trials, received FDA approval, and can be marketed for their approved indication
• Compounded peptides are made by pharmacies for individual patients based on a prescription — they are not FDA-approved drugs
• Research peptides are sold for laboratory research purposes only — not for human use

Most of the confusion in the peptide space comes from people conflating these three categories.

How Peptides Are Different From Proteins and Hormones

This distinction comes up constantly in the peptide industry, and it's worth getting clear.

Peptides vs. Proteins

Proteins are long chains of amino acids — typically more than 50. They fold into complex 3D structures that determine their function. Peptides are shorter, which means they behave differently in the body: they can be more targeted, often penetrate tissues more readily, and typically have shorter half-lives than proteins.

Peptides vs. Hormones

Hormones are a broad category of signaling molecules — some are peptides (insulin, oxytocin, growth hormone), but not all hormones are peptides (testosterone is a steroid hormone, not a peptide). Peptide hormones specifically bind to receptors on cell surfaces and trigger specific biological responses.

The confusion matters because when people talk about "peptide therapy," they often mean peptide hormones — compounds like growth hormone secretagogues, CJC-1295, tesamorelin, or PT-141. These are peptide hormones or hormone-related compounds, and they sit at the intersection of endocrinology, compounding pharmacy, and some of the most active FDA and FTC enforcement in the wellness space.

The Difference Between FDA-Approved Peptides and Compounded Peptides

This is the most important distinction in the entire peptide regulatory landscape.

FDA-Approved Peptide Drugs

These are peptides that have undergone clinical trials, received FDA approval under a New Drug Application (NDA) or Biologics License Application (BLA), and are marketed for specific, approved indications.

Examples of FDA-approved peptide-based drugs:
- Ozempic / Wegovy (semaglutide) — approved for Type 2 diabetes and weight management
- Saxenda (liraglutide) — approved for weight management
- Trulance (plecanatide) — approved for chronic idiopathic constipation
- Vyondys 53 (golodirsen) — approved for Duchenne muscular dystrophy
- Copaxone (glatiramer acetate) — approved for multiple sclerosis
- Forteo (teriparatide) — approved for osteoporosis

These are real drugs. They have FDA-approved labeling, clinical trial data, and established safety profiles for their approved uses.

Compounded Peptides

Compounded peptides are peptides made by pharmacies — typically 503A compounding pharmacies or 503B outsourcing facilities — for individual patients based on a valid prescription. They are not FDA-approved. They are not generics of FDA-approved drugs. They are not substitutes for FDA-approved drugs.

Under Section 503A of the FD&C Act, compounded peptides can be made for patients with a valid prescription when the patient's clinical needs cannot be met by an FDA-approved drug. This is the legal basis for most peptide prescribing in the wellness space.

The FDA has issued specific guidance on compounded peptides, including a list of peptides that are essentially copies of approved drugs and should not be compounded (the "essentially a copy" list). Peptides on this list — including some forms of BPC-157 and KLOW compounds — are enforcement priorities for the FDA.

Research Peptides

Sold as "not for human use" or "for laboratory research only." These are technically legal to sell, but any use that causes them to function as drugs — promoting them for human consumption, marketing them with therapeutic claims — crosses into FDA enforcement territory. Anyone selling research peptides for human use via a website or social media is operating in a legal gray area that frequently becomes a red area.

Why the Peptide Industry Has Grown So Fast

The growth in the peptide wellness space is real and it is significant. A few factors explain it:

GLP-1 recognition. The approval of semaglutide (Ozempic, Wegovy) for weight management in 2021 and 2022 brought peptide science into mainstream consumer awareness in an unprecedented way. Millions of people who had never heard of peptides learned that a peptide could be a powerful tool for metabolic health. The subsequent shortages of GLP-1 drugs — driven partly by off-label use for weight loss — pushed patients toward compounded alternatives, accelerating the growth of the compounding pharmacy industry.

Consumer dissatisfaction with conventional approaches. Testosterone replacement therapy, human growth hormone, and anabolic steroids have been the mainstream options for hormone optimization for decades. Peptides offered a newer, sometimes perceived-as-safer alternative with a different mechanism of action — even when the evidence base for many peptides in wellness contexts was limited.

The telehealth revolution. The expansion of telemedicine, accelerated by pandemic-era regulatory flexibilities, made it dramatically easier for patients to access peptide prescribing providers without traveling to a specialized clinic. A patient in rural Iowa can now access a peptide prescribing telehealth platform in minutes. This convenience drove enormous demand — and enormous provider supply.

Social media amplification. Influencers and content creators discussing their personal peptide protocols — some compliantly, some not — created massive organic awareness. The content ranged from sophisticated medical education to outright illegal disease claims. All of it drove demand.

The Four Legal Lanes Peptide Businesses Actually Operate In

This is where operators need to understand the regulatory framework — and where most of the confusion in the industry comes from. The peptide business landscape breaks down into four distinct regulatory lanes:

Lane 1: Patient-Specific Compounding (503A)

Pharmacies that compound peptides for individual patients based on valid prescriptions. The regulatory foundation is Section 503A of the FD&C Act. Every prescription must be for a specific patient, for a specific clinical need that cannot be met by an FDA-approved drug. This is the most common legitimate model for peptide clinics.

Lane 2: Office-Use Compounding (503B)

Outsourcing facilities that can compound peptides for office use — meaning they can make larger batches available to hospitals, clinics, and practitioners without a specific patient prescription in advance. Regulated under Section 503B of the FD&C Act, which requires FDA registration, compliance with good manufacturing practices, and reporting to the FDA. This is a more heavily regulated model than 503A.

Lane 3: API Supply

Suppliers of Active Pharmaceutical Ingredients (APIs) — the raw peptide compounds — to pharmacies and researchers. API suppliers must ensure their products are for legitimate pharmaceutical or research use and must not be marketing their compounds as finished drugs. The regulatory line for API suppliers is in how the product is marketed and sold.

Lane 4: Telehealth and Clinical Services

Platforms and providers that connect patients with prescribing clinicians — the telehealth layer. This lane is governed by state medical licensing requirements, state telehealth regulations, and federal standards of care. The clinical services lane does not involve manufacturing or dispensing, but it is responsible for the prescribing decision that triggers the compounding relationship.

Most peptide businesses operate across more than one lane simultaneously. A peptide clinic using a telehealth platform to connect patients with providers, routed to a 503A pharmacy, is operating in Lanes 1 and 4. A 503B facility selling office-use products to clinics is operating in Lane 2. Understanding which lanes your business operates in — and ensuring every lane is correctly structured — is the foundation of compliant operation.

What Operators and Consumers Both Get Wrong

Based on the enforcement patterns we've tracked across FDA warning letters, FTC actions, and state board disciplinary proceedings, these are the most common misunderstandings:

"But this peptide is natural." The fact that a peptide occurs naturally in the body does not mean administering it exogenously is legal without a prescription, without FDA approval for the indication, or without appropriate clinical oversight.

"We're not making a drug — we're compounding." Compounding is a legitimate practice, but it is tightly regulated. Compounded peptides are not FDA-approved. Marketing them as equivalent to FDA-approved drugs — or worse, implying they are superior — is a §301(a) violation (unapproved new drug promotion).

"Our pharmacy is FDA-registered, so this is all legal." FDA registration is not approval. It simply means the facility has registered with the FDA. A registered 503A pharmacy can still produce illegally marketed compounded peptides if the clinical justification for the prescription is absent or fabricated.

"The patient asked for this, so we prescribed it." Patient demand is not a clinical indication. Legitimate prescribing requires a provider to make an independent clinical determination that the prescription is medically appropriate.

What This Means for You

If you're a patient exploring peptide therapy: understand what you're taking, why your provider prescribed it, and whether you're receiving an FDA-approved drug or a compounded peptide. Ask your provider these questions. The answer matters.

If you're an operator building a peptide business: the regulatory framework is navigable, but it requires intentionality. The businesses that survive long-term are the ones that built on a genuine clinical model — not on the gray areas of the internet.

If you're somewhere in between: the peptide space is still maturing. The enforcement landscape is tightening. The operators who are still standing three years from now will be the ones who understood the rules early and built accordingly.

Ready to go deeper?

The peptide industry is growing fast — and the regulatory complexity is not getting simpler. AEG Compliance Members have access to the full regulatory framework, draft agreement templates for pharmacy and supplier relationships, and ongoing compliance intelligence for peptide operators.

→ [Join as a Member — $27/month(https://aim-elemental-group-peptide-compliance-awareness.ghost.io/membership/)
→ [See what's in the library →(https://aim-elemental-group-peptide-compliance-awareness.ghost.io/resources/)
→ [Read: The Four Legal Lanes Peptide Businesses Actually Operate In →(https://aim-elemental-group-peptide-compliance-awareness.ghost.io/four-legal-lanespeptide-businesses-2/)

This post is for educational purposes only. It does not constitute medical or legal advice.

Ready to go deeper?

The peptide industry is growing fast — and the regulatory complexity is not getting simpler. AEG Compliance Members have access to the full regulatory framework, draft agreement templates for pharmacy and supplier relationships, and ongoing compliance intelligence for peptide operators.

Join as a Member — $27/month →

This post is for educational purposes only. It does not constitute medical or legal advice.